Dublin, May 30, 2017 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Ulcerative Colitis Market and Forecast Analysis" report to their offering.
Ulcerative colitis is a chronic inflammatory bowel disease that is characterized by inappropriate diffuse inflammation of the rectal and colonic mucosa, which occurs in the innermost layer of the intestinal lining. Ulcerative colitis is a chronic, incurable disease with low mortality that is generally diagnosed in adolescence and early adulthood.
Ulcerative colitis is currently an idiopathic condition, the pathogenesis of which is yet to be fully elucidated. However, it is known to involve an interaction between genetics, the immune system, and environmental factors. Risk factors include ethnicity, family history, antibiotic or non-steroidal anti-inflammatory agent use, and diet. Incidence and prevalence have been increasing over the past two decades in most regions of the world.
It is estimated that in 2015, there were 2.1 million diagnosed prevalent cases of ulcerative colitis in the US, Japan, and five major EU markets (France, Germany, Italy, Spain, and the UK). Over 2015-35, the number of prevalent cases is expected to increase to 2.5 million (16.6% increase).
Key Topics Covered:
1. Treatment: Ulcerative Colitis
- Primary Research Methodology
- Patient Segmentation
- Country Treatment Trees: Crohn's Disease
- Country Treatment Trees: Ulcerative Colitis
- Current Treatment Options
- Prescribing Trends: Crohn's Disease
- Prescribing Trends: Ulcerative Colitis
- Prescribing Influences
- Unmet Needs in Inflammatory Bowel Disease
2. Epidemiology: Ulcerative Colitis
- Disease Background
- Sources and Methodology
- Forecast
- Epidemiologist Insight
- Strengths and Limitations
3. Marketed Drugs: Ulcerative Colitis
- Product profile: Apriso
- Product profile: Delzicol/Asacol HD
- Product profile: Entyvio
- Product profile: Humira
- Product profile: Lialda
- Product profile: Pentasa
- Product profile: Remicade
- Product profile: Simponi
- Product profile: Uceris
4. Pipeline: Ulcerative Colitis
- Clinical Pipeline Overview
- Target Product Profile
- Product profile (late stage): LT-02
- Product profile (late stage): Xeljanz
- Product profile (late stage): etrolizumab
5. Appendix
- Appendix: Marketed Drugs: Ulcerative Colitis
- Appendix: Pipeline: Ulcerative Colitis
For more information about this report visit http://www.researchandmarkets.com/research/87k8xs/ulcerative